In this study, the high expression of IL-6 in patients with MRD+ suggests a potential role for IL-6 in the process of bone marrow metastasis of NB, and the promotion of immune escape by tumor cells, which is expected to become a novel biomarker for monitoring bone marrow metastasis of NB in the future. This evidence concerns the gene IL6 and neuroblastoma.